# Percutaneous sympathetic blockade in complex regional pain syndrome type 1: a prospective clinical investigation on predictors of sympatheticaly maintained pain

Submission date	<b>Recruitment status</b> No longer recruiting	Prospectively registered		
07/06/2006		☐ Protocol		
Registration date 07/06/2006	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	[] Individual participant data		
02/05/2019	Nervous System Diseases			

## Plain English summary of protocol

Not provided at time of registration

## **Contact information**

## Type(s)

Scientific

#### Contact name

Dr J. Geurts

#### Contact details

Academic Hospital Maastricht (AZM) P.O. Box 5800 Maastricht Netherlands 6202 AZ +31 (0)43 3877673 Jgeurt@sane.azm.nl

## Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

## Secondary identifying numbers

BSIK03016

# Study information

#### Scientific Title

Percutaneous sympathetic blockade in complex regional pain syndrome type 1: a prospective clinical investigation on predictors of sympatheticaly maintained pain

#### Acronym

**SYMBLOC** 

## **Study objectives**

The cold phenotype of CRPS1 is associated with a better response to percutaneous sympathetic blockade as opposed to the warm type of CRPS1.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

#### Study design

Non-randomized controlled trial

## Primary study design

Interventional

## Secondary study design

Non randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Complex regional pain syndrome type 1 (CRPS I) (Causalgia)

#### **Interventions**

Upper extremity CRPS-1: percutaneous blockade of stellate ganglion at C7 with one single injection of bupivacaine 0.25%.

Lower extremity CRPS-1: percutaneous blockade of lumbar sympathetic chain at L3 with a single injection of bupivacaïne 0.25%.

## Intervention Type

#### Phase

**Not Specified** 

## Drug/device/biological/vaccine name(s)

Bupivacaine

#### Primary outcome measure

Pain relief in the first week after blockade as measured three times daily in a pain diary where, 0 = no pain and 10 = worst imaginable pain

## Secondary outcome measures

The following predictors of pain relief after sympathetic blockade will be measured:

- 1. Pain intensity on an NRS scale of 0 to 10
- 2. Subjective and objective skin temperature
- 3. Hyper- and hypo-esthesia
- 4. Allodynia
- 5. Hyper- and hypo-algesia
- 6. The presence of dystonia
- 7. Tremor and myoclonus

## Overall study start date

10/04/2006

## Completion date

10/04/2008

# **Eligibility**

## Key inclusion criteria

Adult (18 years or more) male or female patients with CRPS1 as diagnosed by International Association for the Study of Pain (IASP) criteria, with a duration of 12 months or less with moderate to severe pain (mean numerical rating scale [NRS] of more than 4 in the previous week as measured three times daily in a pain diary where, 0 = no pain and 10 = worst imaginable pain) and one extremity involved.

## Participant type(s)

**Patient** 

## Age group

Adult

## Lower age limit

18 Years

#### Sex

Both

## Target number of participants

#### Total final enrolment

49

#### Key exclusion criteria

- 1. Patients of less than 18 years of age
- 2. The existence of significant impairment of blood coagulation or the use of oral anticoagulant medication
- 3. Patients suffering from diabetic polyneuropathia
- 4. Patients who are unlikely to comply with study requirements
- 5. Pregnant women
- 6. CRPS1 with a duration of more than 12 months

#### Date of first enrolment

10/04/2006

#### Date of final enrolment

10/04/2008

## Locations

#### Countries of recruitment

Netherlands

# Study participating centre

Academic Hospital Maastricht (AZM)

Maastricht Netherlands 6202 AZ

# Sponsor information

#### Organisation

Academic Hospital Maastricht (AZM) and Dutch Consortium for Research on Trauma Related Neuronal Dysfunction (TREND)

## Sponsor details

P.O. Box 5800 Maastricht Netherlands 6202 AZ

## Sponsor type

University/education

#### **ROR**

https://ror.org/02d9ce178

# Funder(s)

## Funder type

Government

#### Funder Name

Ministry of Economic Affairs (BSIK03016)

## Alternative Name(s)

Ministry of Economic Affairs, Netherlands Ministry of Economic Affairs, EZ

## **Funding Body Type**

Government organisation

## **Funding Body Subtype**

National government

#### Location

Netherlands

# **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2012	02/05/2019	Yes	No